Moving averages
SMA 200$29.01+14.31%
Company profile
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
SectorHealthcare
IndustryBiotechnology
Market cap$19.92B
P/E ratio25.15
EPS$1.27
Beta0.685
Dividend yield0.00%
52-week high$35.43
52-week low$23.22
Similar stocks in Biotechnology
BNTX
BioNTech SE
RSI 52
VRTX
Vertex Pharmaceuticals Inc
RSI 64
CRSP
CRISPR Therapeutics AG
RSI 54
IOVA
Iovance Biotherapeutics Inc
RSI 66
MRNA
Moderna Inc
RSI 67
VKTX
Viking Therapeutics Inc
RSI 49
SRPT
Sarepta Therapeutics Inc
RSI 67
EDIT
Editas Medicine Inc
RSI 52
NVAX
Novavax Inc
RSI 72
DNA
Ginkgo Bioworks Holdings Inc - Class A
RSI 44
RSI alerts for GMAB
Get an email the moment Genmab AS crosses into oversold or overbought territory. Nothing else, ever.
Add alertData last updated 16 August 2026 at 1:47 AM EDT